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OBJECTIVES
In vitro In vivo
Construction of CRISPR/cas9 system against microRNAs
upregulated in TNBC cases.
Transfection of CRISPR/cas9 system to knockout oncogenic
microRNAs in TNBC cells.
Incorporation of CRISPR/cas9 system in exosomes to
improve intracellular delivery.
Access efficiency knockout of CRISPR/cas9-loaded
exosomes in vitro and in vivo
INTRODUCTION
Treatment is a major clinical challenge due to 
lack of targeted therapy
Dysregulation of microRNAs was involved in the initiation
of oncogenesis. Many microRNAs have been associated to
TNBC due to their overexpression in this cancer subtype.
CRISPR/cas9 is a powerful genome-editing tool able to 
knockout the expression of oncogenic microRNAs
Triple negative breast cancer (TNBC) represents 15-20%
of breast cancer cases (about 2 out of every 10 cases).
Characterized by the absence of three biomarkers:
human epidermal growth factor receptor 2, estrogen and
progestrone receptor.
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Exosomes as a delivery platform of
CRISPR/cas9 system in TNBC
Efficient TNBC therapy
comprising of exosomes loaded
with CRISPR/cas9 system
against oncogenic microRNAs
